Meeting
2023 ASCO Genitourinary Cancers Symposium
Impact of 68Ga-PSMA PET/CT in patients with metastatic castration-resistant prostate cancer (mCRPC) treated with enzalutamide.
Authors
Amelia Altavilla
IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) "Dino Amadori", Meldola, Italy
Amelia Altavilla , Paola Caroli , Emilio Francesco Giunta , Emanuela Scarpi , Virginia Rossetti , Chiara Casadei , Cristian Lolli , Giuseppe Schepisi , Sara Bleve , Maria Concetta Cursano , Lorenzo Gasperoni , Federica Matteucci , Ugo De Giorgi
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session A: Prostate Cancer
Track
Prostate Cancer - Advanced,Prostate Cancer - Localized
Sub Track
Diagnostics and Imaging
Citation
J Clin Oncol 41, 2023 (suppl 6; abstr 48)
DOI
10.1200/JCO.2023.41.6_suppl.48
Abstract #
48
Poster Bd #
B7
Abstract Disclosures
Similar Posters
Poster
2022 ASCO Annual Meeting
Safety and survival outcomes in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) treated with lutetium-177–prostate-specific membrane antigen (177Lu-PSMA) after radium-223 (223Ra): Interim analysis of the RALU study.
First Author: Kambiz Rahbar
Poster
2018 Genitourinary Cancers Symposium
Abiraterone acetate in metastatic castration-resistant prostate cancer post-docetaxel: A “real-life” retrospective analysis of outcomes in a Brazilian public health institution.
First Author: Thais Caroline Menegasso Flores
Poster
2017 Genitourinary Cancers Symposium
First-line chemotherapy (CT) versus anti-androgen therapy (AT) for patients (pts) with metastatic castration-resistant prostate cancer (mCRPC): Individual patient analysis of the Veterans Health Administration (VHA) dataset.
First Author: Guru Sonpavde
Poster
2015 Genitourinary Cancers Symposium
Quantitative imaging by automated bone scan index (BSI) as a response biomarker in standard clinical care of patients with metastatic castration-resistant prostate cancer (mCRPC) treated with enzalutamide.
First Author: Aseem Anand